Company attracts world-leading researchers who discovered the role of mismatch repair biology … Continue reading “NeoPhore Appoints Pioneering Cancer Researchers and Clinicians to Scientific Advisory Board”
Taiho Ventures First Investment in Europe 8 January 2018, Cambridge, UK: STORM … Continue reading “STORM Therapeutics Extends Series A Round to Include New Investor Taiho Ventures”
DelSiTech Ltd, a Finnish drug delivery technology and development company, and C-Tri … Continue reading “DelSiTech Ltd and C-Tri Co. Ltd Sign a Collaboration Agreement to Develop Innovative Drug Delivery Technology Product for Oncology”
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful … Continue reading “LSP RAISES EUR 280 MILLION TO INVEST IN HEALTHCARE INNOVATION”
11 December 2017, Cambridge, UK: STORM Therapeutics, the leading drug discovery company … Continue reading “STORM Therapeutics Announces Appointments to Scientific Advisory Board”
Collaboration by company and founders will offer further insights into DNA repair … Continue reading “NeoPhore Scientific Founders Publish Breakthrough Immuno-oncology Discoveries in Nature”
Geneva, Switzerland, 28 November 2017: iOnctura SA, a recently founded late stage … Continue reading “iOnctura Announces Appointment of Leading International Scientific Advisory Board”
Applications open today for RYSE Early Stage Opportunity Fund London, 27 November … Continue reading “RYSE announces partnership with DigitalHealth.London to invest in early stage digital health businesses”
BY FOUNDER PROFESSOR TONY KOUZARIDES New Drug Target Discovered For Acute Myeloid … Continue reading “STORM Therapeutics announces publication in nature on RNA Epigenetics”
Stockholm, November 20, 2017. Calliditas Therapeutics AB (formerly Pharmalink AB) announced today … Continue reading “Surrogate marker and design of Calliditas Therapeutics’ IgA nephropathy Phase 3 study agreed with the FDA”
Regional license covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan … Continue reading “Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®”
STOCKHOLM, November 15, 2017: The specialty pharmaceutical company Pharmalink AB today announced … Continue reading “Pharmalink is renamed Calliditas Therapeutics”
15th November 2017, Cambridge, UK – Sixth Element Capital LLP (6EC), a … Continue reading “PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company”
6 November 2017, Cambridge, UK: STORM Therapeutics, the drug discovery company focused … Continue reading “STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research”
New platform to focus on investing in unique disruptive technologies and real … Continue reading “RYSE Asset Management LLP (RYSE) launches advisory, wealth and investment management platform”
Novel MINIject device made from STAR® material successfully implanted in 25 patients … Continue reading “iSTAR Medical completes enrolment of first-in-human MIGS trial”
Forendo Pharma, a drug development company developing novel oral treatments for endometriosis … Continue reading “Forendo Pharma nominates world class scientific advisory board and elects Professor Linda Giudice as the Chairperson”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2022 Optimum Strategic Communications All rights reserved.
The Spice Building
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
